Detailed Information on Publication Record
2017
Does First-Trimester Screening Modify the Natural History of Congenital Heart Disease? Analysis of Outcome of Regional Cardiac Screening at 2 Different Time Periods
JIČÍNSKÁ, Hana, P. VLASIN, M. JICINSKY, I. GROCHOVA, V. TOMEK et. al.Basic information
Original name
Does First-Trimester Screening Modify the Natural History of Congenital Heart Disease? Analysis of Outcome of Regional Cardiac Screening at 2 Different Time Periods
Authors
JIČÍNSKÁ, Hana (203 Czech Republic, guarantor, belonging to the institution), P. VLASIN (203 Czech Republic), M. JICINSKY (203 Czech Republic), I. GROCHOVA (203 Czech Republic), V. TOMEK (203 Czech Republic), J. VOLAUFOVA (840 United States of America), J. SKOVRANEK (203 Czech Republic) and J. MAREK (203 Czech Republic)
Edition
Circulation, Philadelphia, Lippincott Williams Wilkins, 2017, 0009-7322
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 18.881
RIV identification code
RIV/00216224:14110/17:00098539
Organization unit
Faculty of Medicine
UT WoS
000396215400012
Keywords in English
congenital heart defects; echocardiography; epidemiology; first-trimester screening; prenatal cardiology
Tags
Tags
International impact, Reviewed
Změněno: 21/3/2018 16:14, Soňa Böhmová
Abstract
V originále
BACKGROUND: The study analyzed the impact of first-trimester screening on the spectrum of congenital heart defects (CHDs) later in pregnancy and on the outcome of fetuses and children born alive with a CHD. METHODS: The spectrum of CHDs, associated comorbidities, and outcome of fetuses, either diagnosed with a CHD in the first trimester (Group I, 127 fetuses) or only in the second-trimester screening (Group II, 344 fetuses), were analyzed retrospectively between 2007 and 2013. Second-trimester fetuses diagnosed with a CHD between 2007 and 2013 were also compared with Group III (532 fetuses diagnosed with a CHD in the second trimester from 1996 to 2001, the period before first-trimester screening was introduced). RESULTS: The spectrum of CHDs diagnosed in the first and second trimesters in the same time period differed significantly, with a greater number of comorbidities (P< 0.0001), CHDs with univentricular outcome (P< 0.0001), intrauterine deaths (P= 0.01), and terminations of pregnancy (P< 0.0001) in Group I compared with Group II. In Group III, significantly more cases of CHDs with univentricular outcome (P< 0.0001), intrauterine demise (P= 0.036), and early termination (P< 0.0001) were identified compared with fetuses diagnosed with CHDs in the second trimester between 2007 and 2013. The spectrum of CHDs seen in the second-trimester groups differed after first-trimester screening was implemented. CONCLUSIONS: First-trimester screening had a significant impact on the spectrum of CHDs and the outcomes of pregnancies with CHDs diagnosed in the second trimester. Early detection of severe forms of CHDs and significant comorbidities resulted in an increased pregnancy termination rate in the first trimester.